Skip to main content


Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study

Fig. 2

Clinical responses in the chronic hepatitis B virus infection (CHB) group and the non-CHB group. a-f Comparison of the rates of patients achieving therapeutic target, remission, American College of Rheumatology (ACR)20/50 responses, and European League Against Rheumatism (EULAR) responses at each visit. g-n Comparison of dynamic disease activity indicators at each visit. o Comparison of dynamic matrix metalloproteinase-3 (MMP-3) levels in female patients at each visit. Data are represented by the median and interquartile range: *p < 0.05, **p < 0.01, ***p < 0.001. CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28, Disease Activity Score 28-joint assessment; Pain VAS, pain visual analog scale; PrGA, provider global assessment of disease activity; PtGA, patient global assessment of disease activity; RAPID3, Routine Assessment of Patient Index Data 3; SDAI, Simplified Disease Activity Index; SJC28, 28-joint swollen joint counts; TJC28, 28-joint tender joint counts 

Back to article page